Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2022

View Archived Issues

NBL-028: a CLDN6-CD137 bispecific antibody for treating CLDN6-positive tumors

QL-401 shows improved blood safety and is efficacious against solid and hematologic cancers

ARTS-021 shows promising antitumor activity in CCNE1-amplified cancer models

Metacrine divulges new HSD17B13 inhibitors

RaQualia Pharma patents CRF2 receptor antagonists

LYL-797, ROR1-targeted CAR T-cell candidate designed using reprogramming technologies

Scorpion Therapeutics describes new EGFR and/or HER2 inhibitors

Cullgen identifies new PROTACs

AstraZeneca presents new PROTACs for cancer

ECCMID 2022: In antibiotic development, scientific ingenuity meets a dysfunctional marketplace

NexImmune's AIM ACT to be studied in Columbia University's PDO models of HPV-associated cancers

Algernon's NP-251 shown to reduce fibrosis in preclinical NASH study

Virpax reports preclinical PK results for VRP-324 for management of seizures

PharmAbcine reports GLP toxicology results for TIE2-activating antibody PMC-403

CIDRAP receives funding to create coronavirus vaccines R&D roadmap

WVE-004 shows promise for treating C9orf72-associated neurologic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...